DFY.TO 0.66AGF.B.TO 0.05CDR.TO 0.33BLX -0.69KINS 0.34MCY -1.24DIS -2.04ATD.TO 0.6
Inex Pharmaceuticals Corp (IEX.TO)

Inex Pharmaceuticals Corp (IEX.TO)

0.00
-0.00 (0.00%)
0 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
COMMENT

Inex Pharmaceuticals Corp(IEX.TO)

Apr 17, 2007
This is a penny stock and they tend to be promoted.
Photo of Kenneth P. Norquay, CMTKenneth P. Norquay, CMT
No
Unlock Rating
$1.10

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Inex Pharmaceuticals Corp(IEX.TO)

Mar 24, 2004
A well-run company. Probably one of the lower risk biotech investments in Canada. Their product Onco TCS should be approved this year. Have a good marketing partnership with Enzon.
Photo of Ed HoEd HoUnlock Rating
$7.43

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Inex Pharmaceuticals Corp(IEX.TO)

May 29, 2003
If you like biotechs, this could be OK. Speculative.
Photo of Andrew McCreathAndrew McCreathUnlock Rating
$4.55

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Inex Pharmaceuticals Corp(IEX.TO)

Apr 04, 2003
Need to get FDA approval. Too speculative for their funds.
Photo of David BaskinDavid BaskinUnlock Rating
$3.69

Stock price when the opinion was issued

biotechnologypharmaceutical
HOLD

Inex Pharmaceuticals Corp(IEX.TO)

Feb 10, 2003
Good cash balance. Their problemsare delays in getting their product to market. Needs a good partner.
Photo of Mike WeirMike WeirUnlock Rating
$3.77

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Inex Pharmaceuticals Corp(IEX.TO)

Jan 16, 2003
Needs approval by FDA. Nice cash balance.
Photo of Mike WeirMike WeirUnlock Rating
$4.14

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Inex Pharmaceuticals Corp(IEX.TO)

Dec 06, 2002
There will be some delay in their filings with FDA.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$4.90

Stock price when the opinion was issued

biotechnologypharmaceutical
WEAK BUY

Inex Pharmaceuticals Corp(IEX.TO)

Mar 21, 2002
In phase 3 trials. Speculative.
Photo of Bruce CooperBruce CooperUnlock Rating
$6.50

Stock price when the opinion was issued

biotechnologypharmaceutical
PAST TOP PICK

Inex Pharmaceuticals Corp(IEX.TO)

Mar 06, 2002
(Was a top pick on Dec 5 no change) Still likes.
Photo of Martin Hubbes, CFAMartin Hubbes, CFAUnlock Rating
$7.15

Stock price when the opinion was issued

biotechnologypharmaceutical
TOP PICK

Inex Pharmaceuticals Corp(IEX.TO)

Dec 05, 2001
A speculative choice, but has a good RISK/RETURN.
Photo of Martin Hubbes, CFAMartin Hubbes, CFAUnlock Rating
$7.55

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Inex Pharmaceuticals Corp(IEX.TO)

May 04, 2001
Just partnered which is good. Good company
Photo of Malvin SpoonerMalvin SpoonerUnlock Rating
$6.70

Stock price when the opinion was issued

biotechnologypharmaceutical
Showing 1 to 11 of 11 entries
  • «
  • ‹
  • 1
  • ›
  • »

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NFLX -5.4$68.95
RIO -0.52$90.15
MAR -4.9$366.24
META -18.53$646.01
AMT 1.14$170.06
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

DFY.TO 0.66$78.28
AGF.B.TO 0.05$22.89
CDR.TO 0.33$3.91
BLX -0.69$59.25
KINS 0.34$20.09

Popular Articles

Latest Sell Signals

NFLX -5.4$68.95
NFLX -5.4$68.95
CAT 3.11$880.28
NFLX -5.4$68.95
DOL.TO 1.92$190.87

Most Recent Experts

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Bruce Campbell (2)

Bruce Campbell (2)

Stone Castle Investment Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

Inex Pharmaceuticals Corp (IEX.TO) Frequently Asked Questions

What is Inex Pharmaceuticals Corp stock symbol?

Inex Pharmaceuticals Corp is a OTC stock, trading under the symbol IEX.TO (previously IEX-T on Stockchase) on the undefined (undefined). It is usually referred to as or IEX.TO

Is Inex Pharmaceuticals Corp a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on IEX.TO (previously IEX-T on Stockchase) on Stockchase. Read the latest expert commentary for Inex Pharmaceuticals Corp.

Is Inex Pharmaceuticals Corp a good investment or a top pick?

Inex Pharmaceuticals Corp was recommended as a Top Pick by Kenneth P. Norquay, CMT on 2007-04-17. Read the latest stock experts ratings for Inex Pharmaceuticals Corp.

Why is Inex Pharmaceuticals Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Inex Pharmaceuticals Corp.

Is Inex Pharmaceuticals Corp worth watching?

Inex Pharmaceuticals Corp is covered by Stockchase experts and is worth watching.